Overview

A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Status:
Completed

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in Asian patients with Type 2 Diabetes who are not well controlled on metformin alone. The safety of this treatment will also be studied.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

AstraZeneca, Bristol-Myers Squibb

Treatments:

Dapagliflozin
Metformin
Pioglitazone